Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Aspirin × Thoracic × Clear all

Phase

Phase 2 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Thoracic 1 Head & Neck 1 Genitourinary 1 Breast 1

Conditions

Interventions

Pemetrexed 20 Carboplatin 19 Cisplatin 18 pembrolizumab 14 Docetaxel 12 Paclitaxel 9 Gemcitabine 7 Gefitinib 5 Drug Therapy 5 Bevacizumab 5 Erlotinib Hydrochloride 4 130-nm albumin-bound paclitaxel 4 anlotinib 3 Radiotherapy 3 Magnetic Resonance Spectroscopy 3 cemiplimab 2 aumolertinib 2 atezolizumab 2 apatinib 2 Standard of Care 2 Radiotherapy, Intensity-Modulated 2 Radiosurgery 2 Leucovorin 2 Dexamethasone 2 trametinib 1 toripalimab 1 tislelizumab 1 spartalizumab 1 sintilimab 1 rofecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02387086 2015-03-12

Gefitinib Combined With Thalidomide to Treat NSCLC

Shaanxi Provincial People's Hospital

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡